First Licensing Deals For Stem Cell Company Accellta

HAIFA, Israel--(BUSINESS WIRE)--First licensing deals for stem cell company Accellta- this month the company announced that it granted worldwide, non-exclusive rights to Miltenyi Biotec to use one of Accellta’s patents in manufacturing and commercialization of Miltenyi Biotec’s proprietary medium for stem cell cultivation. Miltenyi Biotec is active worldwide and is one of the innovative leaders in products, services and clinical applications for biomedical research and cell therapy.

Several months ago, Accellta granted a similar license to Japanese nutrition and health giant, Ajinomoto. The non-exclusive license includes manufacturing and marketing rights of the medium in Japan, for both research and commercial applications. Ajinomoto has operations in 26 countries and encompasses a wide range of food and nutrition products, amino acids, chemicals and pharmaceuticals, with annual revenues exceeding USD 11 billion.

Help employers find you! Check out all the jobs and post your resume.